MoonLake Immunotherapeutics (NASDAQ:MLTX) Insider Sells $877,933.00 in Stock

MoonLake Immunotherapeutics (NASDAQ:MLTX) insider Kristian Reich sold 43,700 shares of the business’s stock in a transaction on Monday, July 20th. The shares were sold at an average price of $20.09, for a total transaction of $877,933.00. Following the sale, the insider directly owned 2,764,746 shares of the company’s stock, valued at $55,543,747.14. This represents a 1.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kristian Reich also recently made the following trade(s):

• On Monday, July 27th, Kristian Reich sold 1,100 shares of MoonLake Immunotherapeutics stock. The stock was sold at an average price of $20.00, for a total transaction of $22,000.00.
• On Tuesday, July 21st, Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $20.02, for a total transaction of $1,001,000.00.
• On Wednesday, June 17th, Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $19.43, for a total transaction of $971,500.00.
• On Monday, June 15th, Kristian Reich sold 50,000 shares of MoonLake Immunotherapeutics stock. The shares were sold at an average price of $18.89, for a total transaction of $944,500.00.

MoonLake Immunotherapeutics Price Performance

Shares of MLTX stock opened at $18.99 on Friday. The company has a debt-to-equity ratio of 0.39, a current ratio of 8.60 and a quick ratio of 8.60. The company has a market capitalization of $1.40 billion, a P/E ratio of -4.91 and a beta of 1.04. The company’s 50-day simple moving average is $19.12 and its two-hundred day simple moving average is $17.85. MoonLake Immunotherapeutics has a one year low of $5.95 and a one year high of $62.75.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.98) earnings per share for the quarter, missing the consensus estimate of ($0.91) by ($0.07). As a group, equities analysts anticipate that MoonLake Immunotherapeutics will post -3.64 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on MLTX shares. HC Wainwright reiterated a “buy” rating and issued a $45.00 target price on shares of MoonLake Immunotherapeutics in a report on Monday, July 20th. BTIG Research restated a “buy” rating and set a $30.00 price target on shares of MoonLake Immunotherapeutics in a research note on Tuesday, June 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 12th. Leerink Partners raised their target price on shares of MoonLake Immunotherapeutics from $24.00 to $29.00 and gave the company an “outperform” rating in a research report on Wednesday, July 1st. Finally, Needham & Company LLC increased their price objective on shares of MoonLake Immunotherapeutics from $25.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Ten investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $24.21.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Weiss Asset Management LP grew its stake in MoonLake Immunotherapeutics by 413.1% in the first quarter. Weiss Asset Management LP now owns 1,708,328 shares of the company’s stock valued at $31,843,000 after purchasing an additional 1,375,367 shares during the last quarter. Candriam S.C.A. lifted its position in shares of MoonLake Immunotherapeutics by 509.0% during the first quarter. Candriam S.C.A. now owns 818,126 shares of the company’s stock valued at $15,250,000 after buying an additional 683,797 shares during the last quarter. UBS Group AG boosted its holdings in shares of MoonLake Immunotherapeutics by 183.4% in the 4th quarter. UBS Group AG now owns 239,020 shares of the company’s stock valued at $3,150,000 after buying an additional 154,673 shares in the last quarter. GSA Capital Partners LLP purchased a new position in shares of MoonLake Immunotherapeutics in the 4th quarter worth approximately $1,176,000. Finally, Fox Run Management L.L.C. grew its position in shares of MoonLake Immunotherapeutics by 531.2% in the 4th quarter. Fox Run Management L.L.C. now owns 71,962 shares of the company’s stock worth $948,000 after buying an additional 60,562 shares during the last quarter. Institutional investors own 93.85% of the company’s stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.